Y-mAbs names Peter Pfreundschuh CFO; outgoing CFO Bo Kruse to assist transition to July 31

Y-mAbs Therapeutics, Inc.

Peter Pfreundschuh appointed CFO and Treasurer effective June 28, 2024; succeeds Bo Kruse who will assist transition through July 31, 2024.
Base salary $500,000; eligible for annual cash bonus up to 45% of base; receives initial option to purchase 170,000 shares and 46,000 RSUs.
Pfreundschuh previously CFO at Voyager, Frequency, UroGen, Sucampo; earlier roles at J&J, AstraZeneca, Ernst & Young.
Company highlights commercial traction with DANYELZA and advancement of SADA-PRIT radioimmunotherapy platform.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bo Kruse

Chief Financial Officer and Treasurer

Y-mAbs Therapeutics, Inc.

Effective: 2024-07-31
Successor: Peter Pfreundschuh
Filed: July 1, 2024, 7:59 PM ET

succeeded Bo Kruse, who is expected to remain available to the Company for a period of time following the conclusion of his employment on July 31, 2024, during which time Mr. Kruse will assist in the transition of his responsibilities and duties.

Appointed

Peter Pfreundschuh

Chief Financial Officer and Treasurer

Y-mAbs Therapeutics, Inc.

Effective: 2024-06-28
Filed: July 1, 2024, 7:59 PM ET

On June 27, 2024, the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) appointed Peter Pfreundschuh to serve as the Company’s Chief Financial Officer and Treasurer, effective June 28, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Bo Kruse departed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..

Action: departing
Role: Chief Financial Officer and Treasurer

Exact text from the filing

succeeded Bo Kruse, who is expected to remain available to the Company for a period of time following the conclusion of his employment on July 31, 2024, during which time Mr. Kruse will assist in the transition of his responsibilities and duties.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Peter Pfreundschuh was appointed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On June 27, 2024, the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) appointed Peter Pfreundschuh to serve as the Company’s Chief Financial Officer and Treasurer, effective June 28, 2024 (the “Effective Date”).

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-24-009643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.